Inaktiver Wert

Andere Sprachen Clearmind Medicine Inc. Canadian Securities Exchange

Aktien

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders	17.04.
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10.04.
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10.04.
Clearmind Medicine CEO Issues Letter to Shareholders	09.04.
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression	27.03.
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China	19.03.
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration	19.03.
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K	19.03.
Clearmind Medicine Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	18.03.
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals	08.03.22
Clearmind Medicine : Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board	14.10.21
Clearmind Medicine : to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20	01.10.21

Keine Ergebnisse zu dieser Suche